m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00706)
Target Name Metalloreductase STEAP2 (STEAP2)
Synonyms
Prostate cancer-associated protein 1; Protein up-regulated in metastatic prostate cancer; PUMPCn; Six-transmembrane epithelial antigen of prostate 2; SixTransMembrane protein of prostate 1
    Click to Show/Hide
Gene Name STEAP2
Chromosomal Location 7q21.13
Family STEAP family
Function
Metalloreductase that has the ability to reduce both Fe(3+) to Fe(2+) and Cu(2+) to Cu(1+). Uses NAD(+) as acceptor (By similarity).
    Click to Show/Hide
Gene ID 261729
Uniprot ID
STEA2_HUMAN
HGNC ID
HGNC:17885
Ensembl Gene ID
ENSG00000157214
KEGG ID
hsa:261729
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
STEAP2 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line ARPE-19 cell line Homo sapiens
Treatment: shMETTL3 ARPE-19 cells
Control: shControl ARPE-19 cells
 GSE202017
Regulation
logFC: 6.65E-01
p-value: 3.16E-05
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Metalloreductase STEAP2 (STEAP2) overexpression inhibited papillary thyroid cancer cell proliferation, migration, and invasion in vitro and inhibited lung metastasis and tumorigenicity in vivo. METTL3 stabilized STEAP2 mRNA and regulated STEAP2 expression positively in an m6A-dependent manner.
Target Regulation Up regulation
Responsed Disease Papillary thyroid cancer ICD-11: 2D10.1
 Disease Info 
Pathway Response Hedgehog signaling pathway hsa04340
Cell Process Epithelial-to-mesenchymal transition
Cell proliferation
Cell migration
Cell invasion
In-vitro Model TPC-1 Thyroid gland papillary carcinoma Homo sapiens CVCL_6298
KTC-1 Thyroid carcinoma Homo sapiens CVCL_6300
B-CPAP Thyroid gland carcinoma Homo sapiens CVCL_0153
In-vivo Model BCPAP cells (5×106) were introduced into the mice by means of subcutaneous injection through the flank area. STEAP2-saRNA or NC-saRNA (n = 6 for each group) was given by intratumoral multipoint injection at an interval of 3 days (5 injections in total) using an in vivo transfection reagent (Entranster -in vivo, Engreen, China) as per the vendor-provided protocol. Tumor volume (V) was monitored and calculated as follows: V = (L×W2)/2. For the in vivo tumor metastasis assay, BCPAP cells (5×106 cells) were administrated into mice through the tail vein. STEAP2-saRNA or NC-saRNA (n = 6 for each group) was given via tail vein injection at an interval of 3 days (8 injections in total).
Thyroid Cancer [ICD-11: 2D10]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary Metalloreductase STEAP2 (STEAP2) overexpression inhibited papillary thyroid cancer cell proliferation, migration, and invasion in vitro and inhibited lung metastasis and tumorigenicity in vivo. METTL3 stabilized STEAP2 mRNA and regulated STEAP2 expression positively in an m6A-dependent manner.
Responsed Disease Papillary thyroid cancer [ICD-11: 2D10.1]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Hedgehog signaling pathway hsa04340
Cell Process Epithelial-to-mesenchymal transition
Cell proliferation
Cell migration
Cell invasion
In-vitro Model TPC-1 Thyroid gland papillary carcinoma Homo sapiens CVCL_6298
KTC-1 Thyroid carcinoma Homo sapiens CVCL_6300
B-CPAP Thyroid gland carcinoma Homo sapiens CVCL_0153
In-vivo Model BCPAP cells (5×106) were introduced into the mice by means of subcutaneous injection through the flank area. STEAP2-saRNA or NC-saRNA (n = 6 for each group) was given by intratumoral multipoint injection at an interval of 3 days (5 injections in total) using an in vivo transfection reagent (Entranster -in vivo, Engreen, China) as per the vendor-provided protocol. Tumor volume (V) was monitored and calculated as follows: V = (L×W2)/2. For the in vivo tumor metastasis assay, BCPAP cells (5×106 cells) were administrated into mice through the tail vein. STEAP2-saRNA or NC-saRNA (n = 6 for each group) was given via tail vein injection at an interval of 3 days (8 injections in total).
References
Ref 1 METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition. Cell Death Dis. 2022 Apr 18;13(4):358. doi: 10.1038/s41419-022-04817-6.